Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02203760 | Pazopanib Vs. Pazopanib Plus Gemcitabine | PHASE2 | ACTIVE NOT_RECRUITING | 58 | — | — | Oct 16, 2019 | Dec 31, 2024 | Nov 15, 2024 | 9 | Germany |
| Arm | Type | Description |
|---|---|---|
| Pazopanib plus Gemcitabine | EXPERIMENTAL | Arm A: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or |
| Pazopanib | ACTIVE_COMPARATOR | Pazopanib 800 mg orally once daily |
| Name | Type | Description |
|---|---|---|
| Pazopanib plus Gemcitabine | DRUG | Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or |
| Pazopanib | DRUG | Pazopanib 800 mg orally once daily |
Inclusion Criteria: 1. Subjects must provide informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up. Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) an...